Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SpectRx sells "non-core" SimpleChoice:

This article was originally published in Clinica

Executive Summary

In a move to further its cervical cancer treatment programme, SpectRx, of Norcross, Georgia, has announced that it is terminating the sales of all SimpleChoice products and has sold its SimpleChoice insulin pump product line to ICU Medical. "With the company focusing on developing its cervical cancer technology, insulin pumps were no longer core to that strategy," a SpectRx spokesperson told Clinica. SpectRx is currently working towards completing patient enrolment into its pivotal of its cervical cancer test, which aims to eliminate painful Pap and HPV samples and deliver immediate results. ICU, the San Clemente, California-based IV therapy specialist has acquired a majority of the assets of Sterling Medivations, the SpectRx subsidiary that developed SimpleChoice, for an undisclosed fee. ICU's purchase adds to its portfolio of insulin pumps, as it already manufactures and develops the Orbit 90 diabetes infusion set.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts